BIOGRAPHICAL SKETCH NAME POSITION TITLE Professor Paul Workman FRS FMedSci 1. Chief Executive and President, The Institute of Cancer Research (ICR), London UK 2. Director, CRUK-ICR Centre in association with The Royal Marsden NHS Trust, London UK 3. Harrap Professor of Pharmacology and Therapeutics, University of London, UK EDUCATION/TRAINING DEGREE INSTITUTION AND LOCATION (if YY FIELD OF STUDY applicable) University of Leicester, UK BSc (Hons) 1973 Biological Sciences University of Leeds, UK PhD 1977 Cancer Pharmacology A. Personal Statement I am an experienced cancer research scientist with extensive leadership and administrative experience in academia and industry. I am passionate about translating our rapidly emerging understanding of fundamental cancer biology with a sense of urgency into new personalized medicines for cancer patients. I am currently Chief Executive and President of The Institute of Cancer Research (ICR), London and Harrap Professor of Pharmacology and Therapeutics at ICR – a college of the University of London. In addition, I am Director of the CRUK-ICR Centre in association with The Royal Marsden NHS Trust (RM). Furthermore, I am the inaugural Director of the ICR-Imperial College Cancer Research Centre of Excellence in Cancer Research which was established in 2016 to bring together – in synergistic convergence science – Imperial’s strengths in engineering, physical, natural, and data sciences and medicine with ICR’s strengths in basic and applied cancer research, as well as forming the basis for an application to become a CRUK Major Centre, addressing all aspects of cancer prevention, early detection and treatment. ICR came top in REF2014 and ICR/RM has been ranked as one of the top four cancer centres in the world for the impact of its publications (Thomson Reuters Evidence). From 1997 to January 2016, I was Head of the Section/Division of Cancer Therapeutics at ICR and Director of the Cancer Research UK Cancer Therapeutics Unit – the largest non-profit cancer drug discovery group globally and recently assessed as the best in world by external peer review. Before that, I was Head of Cancer Bioscience Section at Zeneca Pharmaceuticals (now AstraZeneca) and earlier was at Stanford University, Glasgow University and Cambridge University. I was a scientific founder of the biotechnology companies Piramed Pharma (acquired by Roche for USD 175 million) and Chroma Therapeutics. My personal research focuses on cancer drug discovery, molecular pharmacology and chemical biology – publishing >565 research articles with 19K citations and an H-index of 74 (Web of Science). I have been instrumental in more than 20 drugs entering clinical trials, including protein kinase, PI3 kinase and HSP90 inhibitors. I conceived and exemplified the Pharmacologic Audit Trail for decision-making in preclinical discovery and clinical drug development. I have promoted and exemplified the centre of excellence and team science model for academic drug discovery, while also collaborating extensively with industry. I continue to run an active research laboratory and my current interests are in the discovery and development of innovative personalized medicines; novel drug targets; extending the druggable cancer genome; chemical probes; the HSF1 stress pathway; and overcoming adaptive feedback loops, clonal evolution and drug resistance. As Chief Executive and President of ICR, I have overall responsibility for all aspects of the organization and enjoy the opportunity to guide basic, translational and clinical research. Externally, I am a Non-Executive Director of Storm Therapeutics, the RM and the non-profit Chemical Probes Portal. In addition to numerous previous advisory roles, I am currently a member of a number of advisory boards, PHS 398/2590 (Rev. 06/09) Page 1 Biographical Sketch Format Page serve on the editorial board of several journals, and am Deputy Editor of Molecular Cancer Therapeutics and a Reviews Editor of Cancer Cell. I write, blog and lecture on cancer research, cancer drugs and the drug discovery and development ecosystem. I have received numerous honours and awards (see next section). B. Positions and Honours Positions 1976-79, Postdoctoral Scientist, MRC Clinical Oncology Unit, Cambridge University, UK 1979-83, Limited Tenure Appointment (MRC Grade 2), MRC Clinical Oncology Unit, Cambridge University, UK 1983-87, Tenured Appointment (MRC Grade 1), MRC Clinical Oncology Unit, Cambridge University, UK 1987, Senior Appointment (MRC Grade 2), MRC Clinical Oncology Unit, Cambridge University, UK 1987-1990, MRC Special Appointment (Professorial equivalent), MRC Clinical Oncology Unit, Cambridge University, UK 1990, UICC Visiting Fellow, Stanford University and Stanford Research International, CA, USA 1991-93, Director of Laboratory Research and CRC Professor of Experimental Cancer Therapy, Department of Medical Oncology, CRC Beatson Laboratories, University of Glasgow, UK 1993-97, Head of Bioscience Section, Zeneca Pharmaceuticals (now AstraZeneca) 1997-2016, Director, CRUK Cancer Therapeutics Unit and Head of Division/Section of Cancer Therapeutics, The Institute of Cancer Research, London, UK (ICR) 1997-present, Team Leader, Signal Transduction and Molecular Pharmacology, ICR 1997-present, Harrap Professor of Pharmacology and Therapeutics, ICR 2014, July-November Interim Chief Executive, ICR 2011-2014, Deputy Chief Executive, ICR 2014-present, Chief Executive and President, ICR 2014-present, Director, CRUK-ICR Centre in association with the RM 2016-present, Director, ICR and Imperial College Cancer Research Centre of Excellence Honours 1985 European School of Oncology Award for Excellence in Oncology Research 1990 UICC ICRETT Fellowship 1991 Cancer Research UK Life Fellow 1993 External Professor of Cancer Pharmacology, Institute of Cancer Studies, University of Leeds UK 1986 Visiting Professor in Pharmacology, School of Biological Sciences, University of Manchester UK 1999 Tannlege Olav Aase og Feu Memorial Lecture, Norwegian Cancer Forum 2001 Fellow of the Royal Society of Biology 2002 Fellow of the Academy of Medical Sciences 2002 Perkin Elmer Life Sciences Lecture, British Association for Cancer Research 2002 Merlin Lecture of Cancer Research UK 2003 Bruce Cain Memorial Award Lecture of the New Zealand Society for Oncology 2006 Dutch New Drug Development Office (NDDO) Award for Cancer Drug Development 2007 ICON Distinguished Lecture of the University of Manchester 2007 Fellow of the Royal Society of Medicine 2009 Honorary DSc University of Leicester UK 2009 Tom Connors Award Lecture of the British Association for Cancer Research and National Cancer Research Institute 2010 Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy 2010 Fellow of the Royal Society of Chemistry 2011 Bruce Cain Memorial Award Lecture of the New Zealand Society for Oncology 2012 Lineberger Lecture, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA 2012 American Association of Cancer Research Team Science Award (PW Team Leader) 2012 Royal Society of Chemistry World Entrepreneur of the Year Award 2013 Cancer Research UK Translational Cancer Research Prize (with Laurence Pearl) 2014 International Raymond Bourgine Award for Excellence in Cancer Research 2014 Fellow of the European Academy Cancer Sciences 2015 British Pharmacological Society Putting UK Pharmacology on the Map Award (to ICR) PHS 398/2590 (Rev. 06/09) Page 2 Biographical Sketch Format Page 2016 Fellow of the Royal Society 2016 Evening Standard Progress 1000 list of most influential people in London 2016 Cancer Research Innovation Spain (CRIS) Award for Services to Cancer Research 2017 Honorary DSc University of Leeds UK 2017 Honorary Fellow University of Cumbria 2017 Patrick Johnston Memorial Lecture 2017 Queens’s Anniversary Prize (for drug discovery, to ICR) C. Selected Peer-Reviewed Publications (from a total of >565) 1. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Yu Y-J, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, CAMCAP study group, de Bono J, Attard A, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C, The TCGA consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal D, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics in press. 2. Fok JHL, Hedayat S, Zhang L, Aronson LI , Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P*, Davies F. HSF1: Essential for myeloma cell survival and a promising therapeutic target. Clin Cancer Res in press (*Joint senior author). 3. Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P*. Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Mol Oncol 2017 Oct 24. doi: 10.1002/1878-0261.12148 [Epub ahead of print] (*Joint senior author). 4. Antolin A, Tym JE, Komianou A, Collins I, Workman P*, Al-Lazikani B. Objective, quantitative, data-driven assessment of chemical probes. Cell Chem Biol in press (*Joint senior author). 5. Blagg P, Workman P*. Choose and use your chemical probe wisely to explore cancer biology. Cancer Cell 32 268-270 2017 (*Joint senior author). 6. Workman P, Draetta GF, Schellens JH, Bernards R. How much longer will we put up with $100,000 cancer drugs? Cell 168 579-583 2017.